Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma

Abstract

The prognostic value of CD56 and CD117 expression on myeloma cells is controversial. This study aims to analyze the correlation of CD56 and CD117 expression with cytogenetic abnormalities and survival. A total of 128 patients with newly diagnosed multiple myeloma (NDMM) were recruited in this single-center retrospective study. Flow cytometry and FISH tests of marrow cells were performed for all of the subjects. The statistical methods included a chi-squared test, univariate and multivariate COX regressions, and a Kaplan-Meier survival curve analysis. Regarding the cytogenetics, the incidence of IgH/FGFR3 translocation was more frequent in patients with a negative CD56 (p = 0.003). CD56 negativity was an independent adverse factor associated with a poor prognosis (p = 0.019) and indicated a shorter overall survival (OS) (p = 0.021). Patients with dual negative CD56 and CD117 trended toward a poorer OS (CD56^-CD117^- vs. CD56⁺CD117^-, p = 0.011; CD56^-CD117^- vs. CD56⁺CD117⁺, p = 0.013). In conclusion, CD56 is a prognostic marker that independently affects OS and is associated with adverse cytogenetic abnormalities. Patients with a dual negativity of CD56 and CD117 have a worse clinical outcome.

Keywords: CD117; CD56; cytogenetic abnormality; multiple myeloma; prognosis.

Figure 1

Kaplan-Meier curves for OS and PFS based on CD56 and CD117 expression. (A,B) CD56⁻ had a significantly shorter OS. (C,D) CD117 did not affect PFS or OS. (E) The CD56⁻CD117⁻ group exhibited a considerably shorter OS. (F) CD56⁻CD117⁻ showed a significantly shorter OS.